期刊
LEUKEMIA & LYMPHOMA
卷 61, 期 5, 页码 1201-1210出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2019.1700503
关键词
Multiple myeloma; Chromosome 1; Bortezomib; Outcome
资金
- Fundamental Research Funds for Excellent Talents of Chinese Academy of Medical Sciences
- National Natural Science Foundation of China [81920108006, 81670202, 81630007, 81570181]
- Basic Research Service Fee of the Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences [CIFMS 2019-I2M-2-009, 2017-I2M-1-015, 2017-I2M-1-005, 2016-I2M-3-013]
- CAMS Innovation Fund for Medical Sciences [CIFMS 2019-I2M-2-009, 2017-I2M-1-015, 2017-I2M-1-005, 2016-I2M-3-013]
- National Science and Technology Major Project [2017ZX09304024]
Chromosome 1q21 aberrations in multiple myeloma have attracted much attention for a long time, however, the prognostic value is still under investigation. We confirmed the independent prognostic impact of 1q21 aberrations in this non-randomized clinical study. Our study noted that additional copies and larger clonal size of 1q21 gain did not worsen the outcome. We discovered that 1q21 gain was associated with the acquisition of new chromosome abnormalities and genomic instability, evidenced by the strong correlation between 1q21 gain and complex karyotypes or the acquisition of more than two cytogenetic aberrations. Moreover, 1q21 gain and/or del(17p) were powerful enough to discriminate high-risk patients. Furthermore, 1q21 gain retained unfavorable even when stratified by concurrent presence of t(4;14), especially in the bortezomib arm. Finally, although bortezomib might benefit patients with 1q21 gain, it could not completely overcome its adverse effects, suggesting the necessity of more effective therapies for these patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据